United States Drug Patent 6,465,463: Claim Scope, Exclusivity, Litigation and Patent Landscape for BiDil

US Patent 6,465,463 protected race-specific methods of treating heart failure with hydralazine, or a related hydralazine compound, combined with isosorbide dinitrate or isosorbide mononitrate. The patent covered treatment of a black patient, with several claims adding heart-failure mortality reduction, hypertension, impaired exercise tolerance, reduced renin-angiotensin activity, deficient nitric oxide generation, specific dose ranges, oral solid dosage forms, and concomitant cardiovascular therapies.

The patent was directed to methods of use rather than a new chemical entity. Its enforceable term has ended. The commercial product most closely associated with the patent was BiDil, a fixed-dose hydralazine hydrochloride and isosorbide dinitrate product approved by the FDA in 2005 for the treatment of heart failure in self-identified Black patients. The central commercial claims were claims 45 and 46, together with the more detailed dosing claim 32 and its dependent claims.[1,2]

What does United States Patent 6,465,463 cover?

The patent covers administering a hydralazine compound with an organic nitrate to a black patient for specified heart-failure-related outcomes.

The principal combinations are:

Hydralazine component	Nitrate component	Patient limitation	Therapeutic objective
Hydralazine or specified analog	Isosorbide dinitrate	Black patient	Reduced mortality associated with heart failure
Hydralazine or specified analog	Isosorbide mononitrate	Black patient	Reduced mortality, improved oxygen consumption, quality of life or exercise tolerance
Hydralazine hydrochloride	Isosorbide dinitrate or mononitrate	Black patient with impaired cardiac function and reduced exercise tolerance	Reduced mortality in chronic congestive heart failure
Hydralazine	Isosorbide dinitrate	Black patient with hypertension	Reduced mortality associated with heart failure

The claim set does not require the use of the BiDil brand, a particular tablet design, a particular manufacturer, or a particular fixed ratio of hydralazine to nitrate. It reaches separately administered products if the required drugs are administered as part of the claimed treatment method.

Which claims are the independent claims?

The patent has four principal independent method claims.

Claim 1: broad genus method claim

Claim 1 requires:

A black patient.
Administration of a therapeutically effective amount of at least one hydralazine compound or pharmaceutically acceptable salt.
Administration of isosorbide dinitrate or isosorbide mononitrate.
Treatment directed to reducing mortality associated with heart failure, improving oxygen consumption, improving quality of life, or improving exercise tolerance.

The hydralazine definition is broad and includes hydralazine itself and a group of substituted hydralazine compounds. Claim 5 identifies budralazine, cadralazine, dihydralazine, endralazine, hydralazine, pildralazine and todralazine.

Claim 1 is not limited to congestive heart failure, a specified New York Heart Association class, a particular ejection fraction, a particular dose, or a fixed-dose combination product. That breadth is offset by the requirement that the patient be black and that the treatment be directed to one of the listed clinical outcomes.

Claim 32: dose-specific chronic heart failure claim

Claim 32 narrows the invention to oral treatment of a patient with:

Chronic congestive heart failure.
Impaired cardiac function.
Reduced exercise tolerance.
Hydralazine hydrochloride at approximately 30 to 300 mg per day.
Isosorbide dinitrate at approximately 20 to 200 mg per day, or isosorbide mononitrate at approximately 10 to 120 mg per day.
A black patient.

This claim is commercially significant because its dosing structure maps more closely to the clinical use of hydralazine and isosorbide dinitrate in heart failure.

Claim 45: hydralazine plus isosorbide dinitrate

Claim 45 requires hydralazine, or a pharmaceutically acceptable salt, together with isosorbide dinitrate in a black patient to reduce mortality associated with heart failure.

It does not expressly require hypertension, a specific dose, oral administration, or a fixed-dose formulation.

Claim 46: hypertension limitation

Claim 46 adds hypertension to the elements of claim 45. It covers reducing mortality associated with heart failure in a black patient with hypertension using hydralazine and isosorbide dinitrate.

How do the dependent claims narrow the patent scope?

The dependent claims create multiple fallback positions.

Claims	Added limitation
2, 39, 41, 43	Less active renin-angiotensin system or reduced responsiveness to ACE inhibitors compared with white patients
3 and 44	Hypertension
5 and 6	Specific hydralazine compounds, particularly hydralazine hydrochloride
7	Hydralazine hydrochloride dose of about 30 to 300 mg/day
8	Isosorbide dinitrate dose of about 20 to 200 mg/day
9	Isosorbide mononitrate dose of about 10 to 120 mg/day
10-12	Dinitrate, mononitrate, or both nitrates
13-17, 47-51	Oral, solid, tablet, capsule, sustained-release, sublingual or chewable dosage forms
18-20, 52-54	Same composition or separate components, including administration at about the same time
21-23, 33	Digoxin, including a serum concentration of at least about 0.7 ng/mL
24-27, 33-34	Diuretic therapy and potassium supplementation
28-31, 35-38	ACE inhibitors, beta blockers, lipid-lowering agents, calcium-channel blockers, angiotensin II receptor antagonists or endothelin antagonists
40 and 42	Deficient nitric oxide generation system

Claims 18 through 20 and 52 through 54 are particularly relevant to generic competition. They prevent avoidance based solely on whether hydralazine and nitrate are supplied in one tablet or as separate products, provided the administration satisfies the remaining claim elements.

What formulations are protected by US 6,465,463?

The patent does not principally claim a specific pharmaceutical composition. It claims treatment methods that can use several dosage forms.

The covered administration formats include:

Oral tablets.
Oral capsules.
Sustained-release capsules.
Sublingual tablets.
Sustained-release tablets.
Chewable tablets.
A single composition containing both active ingredients.
Separate hydralazine and nitrate components administered at approximately the same time.

The claims therefore reach both fixed-dose combination products and coadministration of separate hydralazine and nitrate products. The patent does not require a particular excipient, dissolution profile, release mechanism, tablet strength, tablet coating, or hydralazine-to-nitrate ratio.

This distinction matters in patent clearance. A product could avoid a formulation-specific patent while still implicating a method-of-use claim if it is promoted or used for the claimed treatment of a black patient. Conversely, a product supplied without the claimed indication may reduce induced-infringement exposure, depending on labeling, marketing conduct and the facts of use.

What drugs and doses are within the patent claims?

The broad claim set identifies the following hydralazine compounds:

Budralazine.
Cadralazine.
Dihydralazine.
Endralazine.
Hydralazine.
Pildralazine.
Todralazine.

The commercially relevant compound is hydralazine hydrochloride.

The principal dose ranges are:

Active ingredient	Claimed daily range
Hydralazine hydrochloride	About 30 to 300 mg/day
Isosorbide dinitrate	About 20 to 200 mg/day
Isosorbide mononitrate	About 10 to 120 mg/day
Digoxin in claims 23 and 33	Serum concentration of at least about 0.7 ng/mL, with claim 23 specifying approximately 0.7 to 2.0 ng/mL

The use of “about” creates an ordinary claim-construction issue concerning permissible variation around the stated ranges. The ranges are not restricted to a single dose or dosing frequency.

What is the FDA and Orange Book status of US 6,465,463?

BiDil was approved by the FDA on June 23, 2005, as a fixed-dose combination of hydralazine hydrochloride and isosorbide dinitrate for the treatment of heart failure in self-identified Black patients.[2]

The FDA-approved product contained:

Hydralazine hydrochloride: 37.5 mg.
Isosorbide dinitrate: 20 mg.
Recommended initial dosing: one tablet three times daily.
Target dosing: two tablets three times daily, equivalent to 225 mg hydralazine hydrochloride and 120 mg isosorbide dinitrate per day.[2]

The marketed product therefore fell within the dose ranges recited in claim 32.

Historically, US 6,465,463 was listed in the FDA Orange Book for BiDil. The listing created a statutory patent-certification barrier for an ANDA applicant seeking approval of an equivalent product before patent expiry. Because the patent term has ended, the patent no longer provides a current Orange Book-based barrier to approval.

The relevant regulatory milestones are:

Event	Date
US 6,465,463 issued	October 15, 2002
BiDil FDA approval	June 23, 2005
Historical Orange Book listing	US 6,465,463
Patent term	Ended in 2019, subject to the patent’s recorded term adjustment and any applicable regulatory exclusivity
Current patent barrier	None based on enforceable rights under US 6,465,463

The patent’s expiration is separate from FDA regulatory exclusivity. BiDil received regulatory exclusivity associated with its approval, but that period did not extend the patent term indefinitely. The FDA’s Orange Book and exclusivity records control the regulatory timing, while the USPTO patent file controls the patent term.[1,3]

When did US 6,465,463 lose exclusivity?

The patent lost enforceable patent exclusivity in 2019. The precise end date should be read from the USPTO term-adjustment calculation and the historical Orange Book entry rather than inferred solely from the October 2002 issue date.

The patent had no current blocking effect after expiration. A later applicant can pursue an ANDA or another FDA pathway without facing an unexpired patent claim from US 6,465,463. That does not eliminate possible exposure under separate patents, state-law theories, trade-secret rights, or product-specific regulatory requirements.

The patent’s expiration also means that the principal commercial differentiation for BiDil cannot now be maintained through this patent. Any continuing market protection would need to arise from brand recognition, distribution, reimbursement, manufacturing controls, regulatory barriers, or other intellectual-property rights.

Which Paragraph IV challenges affected BiDil?

The patent was vulnerable to ANDA challenges because it was a method-of-use patent covering a known combination of two previously marketed drugs.

A generic applicant could challenge the listed patent through:

Paragraph IV certification that the patent was invalid, unenforceable or would not be infringed.
A section viii statement carving out the patented indication, where the proposed label could lawfully omit the protected use.
A 505(b)(2) application relying on published literature and previously approved hydralazine and nitrate products.

A Paragraph IV challenge would have allowed the patent owner to sue within the statutory window, triggering a potential 30-month stay of FDA approval under the Hatch-Waxman framework. The key legal issue would have been whether the proposed generic label, marketing and foreseeable use induced performance of the claimed treatment method.

The claims presented several potential challenge points:

The requirement that treatment be administered to a “black patient.”
Whether the claimed patient population was adequately supported and enabled.
Whether the mortality, exercise-tolerance and quality-of-life results were adequately linked to the claimed combination.
Whether the claims were anticipated or rendered obvious by earlier hydralazine-nitrate studies.
Whether a generic applicant’s label would induce infringement.
Whether “black patient” and comparative renin-angiotensin or nitric-oxide limitations were sufficiently definite.

No current Paragraph IV litigation can preserve exclusivity because the patent has expired. Historical litigation records should be separated from present launch risk.

What patent litigation affected US 6,465,463?

The patent was associated with Hatch-Waxman disputes involving generic versions of BiDil and with commercial enforcement efforts by NitroMed and its successors. The litigation risk centered on the method-of-use claims, not on ownership of hydralazine or isosorbide dinitrate as chemical substances.

The practical litigation questions were:

Whether the proposed generic label included the heart-failure indication.
Whether the generic product was promoted for use in the claimed black-patient population.
Whether the combination was supplied as a single product or through separate components.
Whether a physician’s prescribing behavior could support induced infringement.
Whether the claims were patentable over the earlier Veterans Administration heart-failure studies.

The record also included disputes over the relationship between earlier clinical evidence and the later race-specific indication. The V-HeFT studies established the therapeutic relevance of hydralazine and isosorbide dinitrate before the BiDil approval. The asserted patent sought protection for selecting and treating a defined patient population based on differential response characteristics.[4,5]

Because the patent is expired, historical infringement disputes no longer create a forward-looking launch block. Settlement terms, if any, remain relevant to historical generic-entry timing but do not revive the patent.

How strong was the patent estate for BiDil?

The patent estate was commercially meaningful but technically narrow.

Strengths

It covered the clinically important hydralazine-plus-nitrate treatment concept.
It included a direct mortality-reduction claim.
It applied to both fixed-dose and separate-component administration.
It included broad hydralazine genus language.
It captured the FDA-approved patient population and dosing structure.
It linked the treatment to a race-specific response rationale.

Weaknesses

The underlying active ingredients were old and widely available.
Earlier clinical work had evaluated hydralazine and isosorbide dinitrate in heart failure.
The claims depended on patient characteristics and treatment intent, which can complicate proof of infringement.
The patent did not provide strong control over the chemical supply of hydralazine or isosorbide dinitrate.
The patent did not broadly claim a novel composition, manufacturing process or formulation technology.
A generic could evaluate a label carve-out for the protected indication.
The race-based limitation created validity, definiteness, enablement and public-policy issues for a challenger to investigate.

The estate was stronger as a regulatory and commercial-use patent than as a compound or formulation estate. Its value depended on maintaining the approved heart-failure indication and controlling the commercial presentation of the combination.

How does US 6,465,463 compare with formulation and manufacturing patents?

US 6,465,463 is primarily a method-of-use patent. It should be distinguished from four other patent categories:

Patent category	Typical protected subject matter	Relevance to BiDil
Compound patent	New active molecule or salt	Weak relevance because hydralazine and nitrates were known
Combination patent	Two or more active ingredients in a composition	Potentially relevant if separately patented
Formulation patent	Release profile, tablet architecture, excipients or stability	Could create narrower product-specific barriers
Method-of-use patent	Treatment of a disease or patient population	Core subject matter of US 6,465,463
Manufacturing patent	Synthesis, purification or scale-up process	Relevant only if the generic uses the protected process

A generic manufacturer could generally source or manufacture hydralazine hydrochloride and isosorbide dinitrate without infringing this patent merely by making the active ingredients. Infringement would require performance, inducement or contribution to a claimed treatment method.

What generic entry risks exist for hydralazine and isosorbide dinitrate products?

Current risk from US 6,465,463 is low because the patent has expired. The principal remaining risks are commercial and regulatory rather than patent-based.

Generic BiDil

A generic fixed-dose hydralazine hydrochloride/isosorbide dinitrate product may face:

FDA bioequivalence requirements.
Product-specific labeling requirements.
Manufacturing and stability requirements.
Potential patents unrelated to US 6,465,463.
Market-access and reimbursement barriers.
Limited demand if the approved indication is narrow.

Separate-component products

Separate hydralazine and isosorbide dinitrate products are less dependent on a single branded combination. Claims 19, 20, 53 and 54 were drafted to address separate-component administration, but those claims no longer block launch after expiration.

Label strategy

Before expiration, a generic might have considered a section viii carve-out. After expiration, the commercial need for such a carve-out is materially reduced. A generic can seek the approved heart-failure indication subject to FDA requirements and any separate unexpired rights.

Is there biosimilar risk for BiDil?

No. BiDil is a small-molecule drug combination, not a biologic. The relevant competitive pathway is an ANDA or, depending on the proposed changes and reliance strategy, a 505(b)(2) application. Biosimilar provisions under the Public Health Service Act do not apply.

The principal competitive products are:

Generic hydralazine hydrochloride.
Generic isosorbide dinitrate.
Generic isosorbide mononitrate.
Fixed-dose hydralazine/isosorbide dinitrate combinations.
Off-label coadministration of separate products.

Which companies challenged or competed with BiDil?

The commercial competitive field included generic manufacturers of hydralazine and nitrate products and companies pursuing approval of equivalent or related combination products. NitroMed was the original commercial sponsor of BiDil. Arbor Pharmaceuticals later acquired BiDil-related commercial rights, and subsequent ownership and distribution arrangements affected commercialization.

The competitive landscape was structurally unusual because:

Both active ingredients were long-established generics.
The branded product relied on a narrow FDA-approved population.
Physicians could prescribe the component products separately.
The method patent, rather than a compound patent, was the principal listed barrier.
The treatment could be replicated clinically without purchasing the branded product.

The key competitive advantage was therefore the approved indication, clinical data package, brand positioning and reimbursement strategy, not control of the underlying molecules.

What was the revenue exposure associated with US 6,465,463?

The patent’s revenue exposure was concentrated in BiDil sales and in the premium associated with the fixed-dose combination. It did not control the much larger markets for hydralazine, isosorbide dinitrate or isosorbide mononitrate generally.

Revenue risk increased sharply after:

FDA approval of BiDil in 2005.
Publication and adoption of guideline-supported use in appropriate heart-failure patients.
Generic availability of the individual components.
Expiration of US 6,465,463 in 2019.
Erosion of the branded fixed-dose combination market.

A valuation model should not attribute all hydralazine or nitrate revenue to this patent. The defensible exposure is the incremental value of the branded, indicated combination and any associated prescribing premium.

What geographic coverage did the patent provide?

US 6,465,463 provided protection only in the United States. The claims could be asserted against conduct involving treatment methods performed in the United States, subject to ordinary territorial and induced-infringement principles.

International protection required separate national or regional patents. A US patent did not block:

Generic manufacture wholly outside the United States.
Foreign sales.
Foreign clinical use.
Foreign regulatory approval.

Commercial diligence should therefore review the corresponding patent family in Europe, Canada, Japan and other target markets separately. Expiration, prosecution history and claim scope may differ by jurisdiction.

Key Takeaways

US 6,465,463 is a method-of-use patent for treating heart failure in black patients with hydralazine or related compounds plus isosorbide dinitrate or isosorbide mononitrate.
Claims 45 and 46 are the clearest mortality-reduction claims for hydralazine plus isosorbide dinitrate.
Claim 32 most closely tracks the BiDil clinical dosing and oral-treatment profile.
The patent covers fixed-dose products and separately administered components.
Dependent claims add hypertension, reduced ACE-inhibitor responsiveness, deficient nitric oxide generation, oral solid dosage forms, digoxin, diuretics, potassium and other cardiovascular drugs.
The FDA approved BiDil on June 23, 2005, for heart failure in self-identified Black patients.
The patent’s enforceable term ended in 2019.
No biosimilar pathway applies because BiDil is a small-molecule combination.
Current generic-entry risk from US 6,465,463 is low because the patent is expired.
Remaining diligence should focus on later formulation, manufacturing, regulatory and commercial rights, not on this expired method patent alone.

FAQs About US Patent 6,465,463

Does US 6,465,463 cover BiDil itself?

No. It primarily covers methods of using hydralazine and an organic nitrate to treat heart failure in a defined patient population. It does not broadly claim hydralazine hydrochloride, isosorbide dinitrate or the BiDil product as chemical substances.

Could a company launch generic hydralazine and isosorbide dinitrate after patent expiration?

Yes, subject to FDA approval and any other applicable unexpired patents or regulatory requirements. US 6,465,463 no longer independently prevents launch.

Does the patent require a fixed-dose combination tablet?

No. The claims expressly cover administration in the same composition and administration as separate components, including administration at approximately the same time.

Why did the patent identify black patients?

The patent was based on the asserted clinical and physiological premise that some black patients with heart failure may have reduced renin-angiotensin activity, reduced ACE-inhibitor responsiveness or impaired nitric oxide generation, making hydralazine-nitrate therapy clinically relevant for that population.

Can a company rely on the patent to support exclusivity outside the United States?

No. US 6,465,463 has no direct legal effect outside the United States. Foreign exclusivity requires separate patents and separate regulatory rights.

References

United States Patent and Trademark Office. (2002). Methods of treating congestive heart failure (U.S. Patent No. 6,465,463).
U.S. Food and Drug Administration. (2005). BiDil prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
Cohn, J. N., Archibald, D. G., Ziesche, S., et al. (1986). Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. New England Journal of Medicine, 314(24), 1547-1552.
Taylor, A. L., Ziesche, S., Yancy, C., et al. (2004). Combination of isosorbide dinitrate and hydralazine in Blacks with heart failure. New England Journal of Medicine, 351(20), 2049-2057.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	7365900	⤷ Start Trial
Canada	2383974	⤷ Start Trial
European Patent Office	1212053	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,465,463

Summary for Patent: 6,465,463